John M Vierling

7PUBLICATIONS
50CO-AUTHORS
Radiation therapyPharmacogenomicsGastroenterology and hepatologyToxicology (incl. clinical toxicology)Clinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 12, 2026
Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

|Apr 13, 2026
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Stuart C Gordon, Alejandra Villamil, Ira M Jacobson

|Dec 01, 2025
Fracture events in patients with primary biliary cholangitis during treatment with seladelpar in the phase III RESPONSE trial.

John M Vierling, Gideon M Hirschfield, Robert P Kustra

|Jun 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.

Cynthia Levy, Palak J Trivedi, Kris V Kowdley

|Oct 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Marlyn J Mayo, John M Vierling, Christopher L Bowlus

|Jun 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.

Gideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein

Pageof 2

Frequent Collaborators

4 joint publications

Gideon M Hirschfield

4 joint publications

Cynthia Levy

4 joint publications

Christopher L Bowlus

3 joint publications

Palak Trivedi